Analyst Price Targets — MEDP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 13, 2026 11:43 am | — | Mizuho Securities | $586.00 | $538.23 | TheFly | Medpace price target raised to $586 from $495 at Mizuho |
| July 8, 2026 9:28 am | Eric Coldwell | Robert W. Baird | $547.00 | $546.29 | TheFly | Medpace downgraded to Neutral from Outperform at Baird |
| July 7, 2026 7:34 am | David Windley | Jefferies | $515.00 | $565.09 | StreetInsider | Jefferies Downgrades Medpace (MEDP) to Hold |
| April 24, 2026 12:33 pm | — | BMO Capital | $400.00 | $402.81 | TheFly | Medpace price target lowered to $400 from $460 at BMO Capital |
| April 24, 2026 11:47 am | Ryan Halsted | RBC Capital | $484.00 | $393.42 | TheFly | Medpace price target lowered to $484 from $522 at RBC Capital |
| April 24, 2026 10:33 am | Eric Coldwell | Robert W. Baird | $477.00 | $393.42 | TheFly | Medpace price target lowered to $477 from $565 at Baird |
| April 24, 2026 9:34 am | Luke Sergott | Barclays | $450.00 | $393.42 | TheFly | Medpace price target lowered to $450 from $500 at Barclays |
| March 6, 2026 11:13 am | Luke Sergott | Barclays | $500.00 | $468.36 | StreetInsider | Barclays Upgrades Medpace (MEDP) to Equalweight |
| February 13, 2026 10:19 am | David Windley | Jefferies | $560.00 | $416.04 | TheFly | Medpace upgraded to Buy from Hold at Jefferies |
| February 11, 2026 1:44 pm | — | Truist Financial | $539.00 | $431.17 | TheFly | Medpace price target lowered to $539 from $555 at Truist |
Latest News for MEDP
Investors interested in Medical Services stocks are likely familiar with Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.
On July 07, 2026, Medpace Holdings Inc (MEDP) shares fell 3.4% today to a current price of $546.29. The stock has experienced significant volatility, trading wi
MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.
MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MEDP.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.